FLT3-TAZ Signaling as a Driver of Drug Resistance in Blast Phase Chronic Myeloid Leukemia

Study Background and Research Question

Chronic myeloid leukemia (CML) is primarily managed with BCR::ABL1 tyrosine kinase inhibitors (TKIs), allowing most patients to achieve long-term disease control. However, in a subset of patients, disease progression to accelerated or blast phase (BP-CML) occurs, often accompanied by the emergence of drug resistance and poor clinical outcomes. While BCR::ABL1 mutations account for some resistance, the contribution of alternative signaling pathways remains underexplored. Shin et al. (2023) address a critical question: Can FLT3, a well-known oncogenic driver in acute myeloid leukemia (AML), also mediate resistance and therapeutic vulnerability in BP-CML?

Key Innovation from the Reference Study

The central innovation of the study is the repositioning of FLT3 not only as a marker but also as a functional driver of TKI resistance in BP-CML. By demonstrating that FLT3 expression activates a specific signaling axis—FLT3-JAK-STAT3-TAZ-TEAD-CD36—that confers resistance to diverse BCR::ABL1 TKIs, the study defines a previously unrecognized FLT3+ BP-CML patient subset with markedly inferior prognosis. This work provides a mechanistic rationale for targeting FLT3 in combination with BCR::ABL1 inhibitors to overcome resistance in advanced CML, bridging concepts from AML research into the CML setting.

Methods and Experimental Design Insights

To address their hypothesis, Shin et al. employed a multi-pronged approach:

• Generation of CML cell lines expressing FLT3 and resistant to BCR::ABL1 TKIs, enabling mechanistic dissection of resistance pathways.
• Enrollment of a phase-specific CML patient cohort, including both unpaired and serially paired samples, to correlate FLT3 expression with disease progression and outcomes.
• Multi-omics characterization—encompassing transcriptomics, proteomics, and phospho-proteomics—of patient-derived samples and xenograft models to identify pathway activation and therapeutic vulnerabilities.
• Functional validation using pharmacological FLT3 inhibition (e.g., midostaurin, ponatinib) in cell-based assays and mouse xenograft models.

Diagnostic methods were optimized to detect FLT3 protein expression and subcellular localization, further refining patient stratification.

Protocol Parameters

• FLT3 expression modeling: Use lentiviral or plasmid-based transduction to introduce FLT3 into CML cell lines prior to TKI resistance induction.
• Drug resistance selection: Stepwise exposure to escalating concentrations of BCR::ABL1 TKIs (e.g., imatinib, dasatinib, ponatinib) over 2–3 weeks to generate resistant derivatives.
• FLT3 autophosphorylation inhibition assay: Treat cells with selective FLT3 inhibitors (e.g., 1–10 nM Quizartinib or midostaurin) for 1–2 hours before assessing FLT3 and STAT3 phosphorylation by immunoblot.
• In vivo xenograft modeling: Inject FLT3+ BP-CML cells into immunodeficient mice; initiate FLT3 inhibitor treatment (e.g., 1 mg/kg oral dosing) when tumors are palpable; monitor tumor burden and survival endpoints.
• Patient sample analysis: Perform flow cytometry and immunohistochemistry to quantify FLT3 expression and correlate with disease phase and clinical outcome.

Core Findings and Why They Matter

The study’s core findings include:

• FLT3 is upregulated in a significant subset of BP-CML patients, and its expression correlates with poor prognosis compared to FLT3-negative cases (reference).
• FLT3 expression activates the JAK-STAT3-TAZ-TEAD-CD36 pathway, driving resistance to multiple BCR::ABL1 TKIs independently of canonical BCR::ABL1 mutations.
• Pharmacological FLT3 inhibition restores TKI sensitivity and promotes apoptosis in FLT3+ BP-CML cells, both in vitro and in mouse xenograft models. Notably, combining FLT3 inhibitors with BCR::ABL1 TKIs, or using ponatinib alone, can overcome resistance.

These findings suggest that FLT3+ BP-CML represents a distinct high-risk group and support the clinical investigation of combined FLT3 and BCR::ABL1 inhibition in this setting.

Comparison with Existing Internal Articles

Several internal articles detail best practices for FLT3 inhibition in AML models, focusing on the use of Quizartinib (AC220) for selective, high-sensitivity assays (e.g., internal article). These resources emphasize Quizartinib's role in dissecting FLT3-driven signaling and modeling resistance mechanisms in AML. The work by Shin et al. extends these concepts into CML, demonstrating that similar FLT3-centric workflows are relevant for understanding and overcoming drug resistance in BP-CML—not just AML. The ability to model FLT3-driven resistance, as optimized in AML studies, is now shown to be essential for CML research investigating cross-lineage resistance phenomena. Additionally, protocols for FLT3 autophosphorylation inhibition and in vivo FLT3 inhibition in mouse xenograft models, widely used in AML, are directly applicable to the CML context described by Shin et al.

Limitations and Transferability

While the study robustly links FLT3 signaling to drug resistance in BP-CML, several limitations should be noted:

• The proportion of BP-CML patients with high FLT3 expression may vary across cohorts and detection platforms.
• Therapeutic benefit of FLT3 inhibition in FLT3+ BP-CML was established in preclinical models; prospective clinical trials are required to confirm efficacy and safety in patients.
• Resistance mutations within FLT3 itself, as seen in AML, could potentially limit the long-term utility of FLT3 inhibitors in CML, necessitating ongoing resistance monitoring.

Nevertheless, the transferability of FLT3 inhibition protocols from AML to CML is well-supported, particularly for researchers seeking to model and reverse drug resistance in advanced-phase disease.

Research Support Resources

For laboratories aiming to replicate or extend these findings, Quizartinib (AC220) (SKU A5793) is a potent, selective FLT3 inhibitor suitable for both in vitro FLT3 autophosphorylation inhibition assays and in vivo xenograft studies. As reported in the product information, Quizartinib exhibits nanomolar potency and high selectivity, making it a valuable tool for dissecting FLT3-dependent resistance mechanisms in both AML and CML workflows. For additional methodological guidance, readers may consult internal articles such as "Quizartinib (AC220): A Selective FLT3 Inhibitor for Acute..." and "Quizartinib (AC220): Precision FLT3 Inhibition in AML Research" for scenario-driven protocols and troubleshooting strategies. As always, researchers should consider the compound's storage and solubility requirements and remain vigilant for potential resistance mutations during chronic exposure.